Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease

被引:650
作者
Georganopoulou, DG
Chang, L
Nam, JM
Thaxton, CS
Mufson, EJ
Klein, WL
Mirkin, CA
机构
[1] Northwestern Univ, Dept Neurobiol & Physiol, Evanston, IL 60208 USA
[2] Northwestern Univ, Dept Chem, Evanston, IL 60208 USA
[3] Northwestern Univ, Inst Nanotechnol, Evanston, IL 60208 USA
[4] Rush Univ, Med Ctr, Dept Neurol Sci, Chicago, IL 60612 USA
关键词
bio-barcode;
D O I
10.1073/pnas.0409336102
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The recently developed ultrasensitive bio-barcode assay was used to measure the concentration of amyloid-beta-derived diffusible ligands (ADDLs), a potential soluble pathogenic Alzheimer's disease (AD) marker, in the cerebrospinal fluid (CSF) of 30 individuals. ADDL concentrations for the subjects diagnosed with AD were consistently higher than the levels in the CSF taken from nondemented age-matched controls. Studies of ADDLs or for any other potential pathogenic AD markers in CSF have not been possible because of their low concentration in CSF (<1 pM). This study is a step toward a diagnostic tool, based on soluble pathogenic markers for the debilitating disease.
引用
收藏
页码:2273 / 2276
页数:4
相关论文
共 32 条
[1]   Evaluation of CSF-tau and CSF-Aβ42 as diagnostic markers for Alzheimer disease in clinical practice [J].
Andreasen, N ;
Minthon, L ;
Davidsson, P ;
Vanmechelen, E ;
Vanderstichele, H ;
Winblad, B ;
Blennow, K .
ARCHIVES OF NEUROLOGY, 2001, 58 (03) :373-379
[2]   CSF markers for incipient Alzheimer's disease [J].
Blennow, K ;
Hampel, H .
LANCET NEUROLOGY, 2003, 2 (10) :605-613
[3]   CSF biomarkers for mild cognitive impairment [J].
Blennow, K .
JOURNAL OF INTERNAL MEDICINE, 2004, 256 (03) :224-234
[4]   Patterns of brain activation in people at risk for Alzheimer's disease [J].
Bookheimer, SY ;
Strojwas, MH ;
Cohen, MS ;
Saunders, AM ;
Pericak-Vance, MA ;
Mazziotta, JC ;
Small, GW .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (07) :450-456
[5]  
Braak H, 1998, J NEURAL TRANSM-SUPP, P127
[6]   NEUROPATHOLOGICAL STAGING OF ALZHEIMER-RELATED CHANGES [J].
BRAAK, H ;
BRAAK, E .
ACTA NEUROPATHOLOGICA, 1991, 82 (04) :239-259
[7]  
Calderón-González PL, 2004, REV NEUROLOGIA, V38, P422
[8]   Femtomole immunodetection of synthetic and endogenous amyloid-β oligomers and its application to Alzheimer's disease drug candidate screening [J].
Chang, L ;
Bakhos, L ;
Wang, ZQ ;
Venton, DL ;
Klein, WL .
JOURNAL OF MOLECULAR NEUROSCIENCE, 2003, 20 (03) :305-313
[9]   Self-assembly of Aβ1-42 into globular neurotoxins [J].
Chromy, BA ;
Nowak, RJ ;
Lambert, MP ;
Viola, KL ;
Chang, L ;
Velasco, PT ;
Jones, BW ;
Fernandez, SJ ;
Lacor, PN ;
Horowitz, P ;
Finch, CE ;
Krafft, GA ;
Klein, WL .
BIOCHEMISTRY, 2003, 42 (44) :12749-12760
[10]   Alzheimer's disease: treatments in discovery and development [J].
Citron, M .
NATURE NEUROSCIENCE, 2002, 5 (Suppl 11) :1055-1057